d4T (Stavudine, Zerit): Research
- Rapid Drop in Mitochondria in Fat Biopsies Within Four Weeks of d4T Use (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- High Prevalence of Peripheral Neuropathy in Children Taking d4T in Rural South Africa (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- AIDS 2012: New Drugs and Formulations (August 1, 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- High Prevalence of d4T-Associated Lipodystrophy Including Lipoatrophy in Children (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- d4T Toxicity Risk 7-Fold Higher When Started With TB Treatment (June 18, 2009)
From aidsmap.com
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
- Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Both Tenofovir and Stavudine Well Tolerated in HCV-Coinfected Patients (July 12, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
In Positively Aware, from Test Positive Aware Network
- Predicting Lipoatrophy After Treatment Initiation (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- More Results Reported on Study 903: Tenofovir + 3TC + Efavirenz Vs. d4T + 3TC + Efavirenz (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Forty-Eight Week Data From FTC-d4T Comparison in Treatment-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- For Potency Tenofovir Equals d4T but Tenofovir Beats d4T With Less Frequent and Common Side Effects (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Lack of Interaction Between Stavudine Extended-Release Formulation and Tenofovir Disoproxil Fumarate (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Efficacy and Safety of Tenofovir DF Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients: 96-Week Preliminary Interim Results (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- New Questions About an Old Combination -- ddI + d4T (January 2003)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
